Doctors may be able to detect head and neck cancers more promptly with the help of saliva.
DNA from tumors can appear in the saliva and blood plasma of patients with head and neck cancers, researchers report June 24 in Science Translational Medicine. This DNA could help identify cancer, or its recurrence, at an early stage. Previous studies have suggested using tumors’ distinctive DNA to detect cancer, says head and neck surgical oncologist Nishant Agrawal of Johns Hopkins University School of Medicine, a coauthor of the paper. This study identified head and neck cancers with surprising accuracy, he says.
The results suggest that it may be possible to detect cancer in saliva from high-risk patients even before symptoms develop, says epidemiologist Eduardo Franco of McGill University in Montreal. “That would be good, because we don’t have any screening test for head and neck cancer,” he says. More than 50,000 Americans are diagnosed with head and neck cancers annually, accounting for about 3 percent of cancers in the United States.
A saliva test could be administered at a dentist’s office or even at home, says cancer geneticist Bert Vogelstein of Johns Hopkins, one of the study’s coauthors.
Researchers found tumor DNA in saliva and blood plasma samples from head and neck cancer patients. Saliva samples were most effective for detecting cancers in the oral cavity, while plasma samples picked up most cancers lower in the throat and neck. Sampling both blood and plasma identified cancers in 96 percent of patients tested.
Credit: Wang et al/Science Translation Medicine 2015
Tumors shed DNA fragments into surrounding bodily fluids. These fragments can contain distinctive genetic changes associated with cancer, and may also contain DNA from human papillomavirus, which causes an increasing fraction of head and neck cancers.
In the new study, saliva samples revealed such tumor DNA in 100 percent of tested patients with oral cavity cancer. Plasma samples picked up tumor DNA in 86 to 100 percent of patients with cancers lower in the throat and neck. Testing both plasma and saliva revealed tumor DNA in 96 percent of patients studied.
Tumor DNA appeared in every patient with early stage cancer and indicated the presence of recurring cancers before clinical diagnoses. Whether initial or recurrent, detecting cancer early can improve quality of life and survival rates, Agrawal says.
Determining if tumor DNA found in saliva and blood plasma can adequately predict cancer will require long-term sampling, says otolaryngologist Jennifer Grandis of the University of California, San Francisco. Franco expresses concern that no completely healthy individuals were tested for comparison. Larger experiments with better controls will come next, Vogelstein says.
Still, Franco and Grandis agree that the study is an encouraging start.
“There’s good reason to be excited,” Franco says. “This is very promising.”